Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Braze Inc (BRZE) vs Tilray Brands Inc (TLRY) Price & Performance

Braze IncTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Braze Inc vs Tilray Brands Inc — how do they compare? Braze Inc trades at $26.99 (market cap $2.95B), while Tilray Brands Inc trades at $4.38 (market cap $540.74M). The key difference: Braze Inc is far larger — about 5.5× Tilray Brands Inc's market cap, and Braze Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

BRZETLRY
Market Cap
$2.95B$540.74M
Sector
TechnologyHealth
52-Week High
$36.19$21.00
52-Week Low
$15.79$4.31
Enterprise Value
$2.64B$637.89M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Braze Inc

Braze (BRZE) trades at $26.60, up 5.85% with strong bullish momentum. The stock shows robust revenue growth, increasing from $238M in 2022 to $593M in 2025, though profitability remains negative with a -15.51% net margin. Technical indicators show bullish moving averages but overbought RSI levels. Recent news highlights Goldman Sachs initiation and strong Q1 2027 results with accelerating revenue growth and AI-driven customer engagement tools.

Outlook remains positive with 96% analyst buy ratings and $34.78 consensus target, representing 31% upside. Key risks include persistent losses despite revenue growth and competitive pressures in customer engagement software. The company's AI capabilities and fourth straight quarter of organic revenue acceleration provide growth catalysts, but investors should monitor profitability improvements.

Tilray Brands Inc

TLRY trades at $4.46, up 0.9% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, though revenue grew to $821.31 million. Analyst consensus is cautious with 65% hold ratings, and recent news highlights expansion in medical cannabis and new product launches.

The outlook remains challenged by persistent losses and high debt levels, but low valuation ratios like P/S of 0.54 and P/B of 0.35 may attract value investors. Key risks include profitability struggles and regulatory uncertainty, while potential catalysts include international expansion and upcoming earnings on July 28, 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Braze Inc

Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.

Read more on BRZE

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY